Drug Profile
Prusogliptin - CSPC ZhongQi Pharmaceutical Technology/National Health Research Institutes/ScinoPharm
Alternative Names: DBPR-108; Diabetes therapeutic - ScinoPharm/National Health Research InstitutesLatest Information Update: 20 Apr 2023
Price :
$50
*
At a glance
- Originator National Health Research Institutes
- Developer CSPC ZhongQi Pharmaceutical Technology; National Health Research Institutes
- Class Amines; Antihyperglycaemics; Fluorobenzenes; Nitriles; Pyrrolidines; Small molecules
- Mechanism of Action Dipeptidyl peptidase 4 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Type 2 diabetes mellitus
Most Recent Events
- 27 Jun 2022 CSPC ZhongQi Pharmaceutical Technology completes a phase-III trial in Type 2 diabetes mellitus (In the elderly) in China (PO) (NCT04161430)
- 13 Apr 2022 CSPC ZhongQi Pharmaceutical Technology completes a phase I trial in type 2 diabetes mellitus (In adults, In the elderly) in China (NCT05146869)
- 31 Dec 2021 CSPC ZhongQi Pharmaceutical technology completes a phase I pharmacokinetic trial (In adults, In the elderly, In volunteers) in China (PO, Tablet) (NCT04859439)